Achieving patient centricity: 4 key lessons from orphan disease companies
Orphan drugs – leading the way in patient centricity
The need to increase patient centricity in pharma is currently a hot topic in the industry, but in the orphan drug / rare disease space it has been a reality for many years.
Read the latest article from Executive Insight and learn the 4 key lessons that are crucial for true patient engagement!
Brought to you by Executive Insight
Patient Centricity
Everyone talks about it today, Patient Centricity, Patient Engagement, Voice of the Patient, Patient Empowerment.
But what do most pharma companies do so far?
Maybe run a patient ad board once, provide an app to track the disease, or develop a disease website for patients. But... is this real patient engagement?
Rare disease companies have always been very close to their patients. Let's learn from them!
- Bring R&D and patients together: Researchers will better understand what really matters to patients
- In clinical development, let patients provide input on trial design: Increase trial success rate and ensure endpoints are patient-relevant
- In Market Access, make patients part of the value story for new treatments: Easier to demonstrate what patients value out in the real world
- Move beyond just another website or app: Let patients design services that address a true need
Honest patient engagement is a win-win:
- Pharma shapes products that have a market
- Patients get what they really need
